Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 60

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 60
---
s, on the one hand, to the Company’s Net Loss over the three years presented in the table, on the other.

CAP VS. NET LOSS

| Compensation Actually Paid (PEO) |     | Avg. Compensation Actually Paid (Non-PEO NEOs) |     | Net Loss |

#### 50Mirum Pharmaceuticals2025 Proxy Statement

#### TABLE OF CONTENTS

#### Executive Compensation

#### CAP and Cumulative TSR
The chart below shows the relationship between the CAP to our PEO and the average CAP to our non-PEO NEOs, on the one hand, to the Company’s cumulative TSR over the three years presented in the table, on the other.

CAP VS. CUMULATIVE TSR

| Compensation Actually Paid (PEO) |     | Avg. Compensation Actually Paid (Non-PEO NEOs) |     | Cumulative TSR (based on $100 investment on December 31, 2021) |

Cumulative TSR of the Company and Cumulative TSR of the Peer Group

The chart below shows the relationship between the Company’s three-year cumulative TSR to the three-year cumulative TSR of the companies in the Nasdaq Biotechnology Index.

CUMULATIVE TSR OF COMPANY VS. PEER GROUP

| Cumulative TSR (based on $100 investment on December 31, 2021) |     | NASDAQ Biotechnology Index TSR (based on $100 investment on December 31, 2021) |

#### Mirum Pharmaceuticals2025 Proxy Statement51

#### TABLE OF CONTENTS

#### Executive Compensation

#### CAP and Net Product Sales
The chart below shows the relationship between the CAP to our PEO and the average CAP to our non-PEO NEOs, on the one hand, to the Company’s net product sales over the three years presented in the table, on the other.

CAP VS. NET PRODUCT SALES

| Compensation Actually Paid (PEO) |     | Avg. Compensation Actually Paid (Non-PEO NEOs) |     | Net Product Sales |

All information provided above under the “Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing of the Company under the Securities Act or the Exchange Act whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference.

#### 52Mirum Pharmaceuticals2025 Proxy Statement

#### TABLE OF CONTENTS

#### Executive Compensation
Policies and Practices Related to